"LPancreas represents a transformative leap in diabetes care, offering early detection of β-cell decline to empower prevention and personalized treatment. ”
Prof. Ralph DeFronzo
world pioneer in diabetes research and treatment
world pioneer in diabetes research and treatment
Estimate Pancreatic Decline
- Direct informed treatment choice
- Support correct timely interventions
- Identify high-risk individuals
- Increase patient awareness
- Prevent diabetic complications
- Improve Quality of Life
- Reduce Healthcare Costs
- Improve treatment response, fostering health & well-being
An Innovative Approach to Combating Diabetes
PREDIABETES
10% of Global Population has Prediabetes
Screening and Prevention
Informed timely interventions
DIABETES TYPE II
>1/2 Billion w/ Diabetes 2 (2M New Cases/Year)
Precision Treatment
Informed treatment choice
LADA
One out of Ten Diabetes Cases
Accurate LADA diagnosis
(Latent Autoimmune Diabetes in Adults)
DIABETES TYPE I
8.4 Million Individuals Suffer from Diabetes type 1
Immunotherapy companion diagnostics
GESTATIONAL DIABETES
10% of pregnacies
Screening for after-birth effects of gestational diabetes
- Blood-based analysis
- Standard PCR lab technology
- Diagnostic kit for 50 tests
- Smart application
- Score for pancreatic decline
How it works: a unique innovation in diabetes
1
Liquid Biopsy
Minimally-invasive dynamic mirror of
the pancreas
2
Epigenetic Biomarker Panel
Combination of tissue specific biomarkers (not a single one) providing a stronger predictive
value
3
Automated Machine Learning
Use our LPancreas dashboard and our advanced AI modeling
FAQ
LPancreas is a product of ABCureD PC.
The test is implemented in a standard biopathology lab.
LPancreas is a minimally-invasive test. It requires a standard blood-sampling by a health professional in the lab.
The result can typically be delivered after one working day.
The test is based on standard PCR methodology. The PCR result is fed into a smart app to produce a score indicative of pancreatic decline.
The test demonstrates the highest ever reported performance for a model in detecting diabetes. See Karaglani et al., JCM 2022.
There is no medical alternative for detecting pancreatic cell-loss.
LPancreas complements current medical practice into diabetes diagnosis and monitoring.
The practitioner has an insight about the progress of patient’s pancreatic decline, indicative of the progress of the pathology.
LPancreas is designed to transform lives and revolutionize healthcare management. With our cutting-edge technology, users can experience an enhanced quality of life, ensuring a healthier and more fulfilling life. By predicting their future, patients can significantly reduce healthcare costs, alleviating financial burdens while accessing comprehensive health solutions. Empowering users with valuable insights, our platform facilitates informed decisions by their doctors, leading to timely and correct interventions. Moreover, our advanced system promotes improved treatment responses, fostering overall health and well-being. Emphasizing personalized care, our product enables tailored management through lifestyle modifications, effectively preventing the onset of diabetes.
Implemented with the support of
